Market closedADR

Ascendis Pharma/$ASND

14:30
15:25
16:15
17:10
18:00
1D1W1MYTD1Y5YMAX

About Ascendis Pharma

Ascendis Pharma AS is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.

Ticker

$ASND
Trading on

Industry

Biotechnology

Headquarters

Hellerup, Denmark

Employees

879

Ascendis Pharma Metrics

BasicAdvanced
$8.3B
Market cap
-
P/E ratio
-$7.77
EPS
0.65
Beta
-
Dividend rate
$8.3B
0.65
$161.00
$111.09
490K
1.161
0.806
-348.263
-810.38
-2.88%
-20.07%
499.54%
23.27
-85.23
-81.78
-29.029
115.54%
-30.33%
357.65%
-1.09%

What the Analysts think about Ascendis Pharma

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Ascendis Pharma stock.

Ascendis Pharma Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Ascendis Pharma Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ASND

$

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Ascendis Pharma stock?

Ascendis Pharma (ASND) has a market cap of $8.3B as of December 26, 2024.

What is the P/E ratio for Ascendis Pharma stock?

The price to earnings (P/E) ratio for Ascendis Pharma (ASND) stock is 0 as of December 26, 2024.

Does Ascendis Pharma stock pay dividends?

No, Ascendis Pharma (ASND) stock does not pay dividends to its shareholders as of December 26, 2024.

When is the next Ascendis Pharma dividend payment date?

Ascendis Pharma (ASND) stock does not pay dividends to its shareholders.

What is the beta indicator for Ascendis Pharma?

Ascendis Pharma (ASND) has a beta rating of 0.65. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.